Issue 24 - The Cancer Letter

<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Vol.

39

No.

24

June 14, 2013Jun 14, 2013

DOWNLOAD THE PDF

Advocacy Group Urges FDA to Sift Through Avastin Glioblastoma Data—Agency Accepts

Guest Editorial: Myriad Ruling Becomes a Textbook Case Of How Not To Manage a Patent Portfolio, by Robert Cook-Deegan

Patenting the Gene: Cancer Advocates and Industry Diverge on Myriad Ruling

FASEB: Focus on Research Funding, Not PR

MD Anderson Researcher Charged With Placing Ethylene Glycol In Colleague’s Coffee

Recent Issues

Volume 52 | Issue 09 - March 06, 2026

Volume 52 | Issue 08 - February 27, 2026

Volume 52 | Issue 07 - February 20, 2026

Volume 52 | Issue 06 - February 13, 2026

Volume 52 | Issue 05 - February 06, 2026

Volume 52 | Issue 04 - January 30, 2026